AIB Data Centers Inc., specializing in AI and high-performance computing infrastructure, announced a virtual investor roadshow on October 22, 2026. CEO Jerry Tang and CFO Jolienne Halisky will discuss the company's business model, recent milestones, customer agreements, and growth opportunities. The event will include a live Q&A session, providing investors insight into AIB's development strategy and financing plans. This presentation aims to update stakeholders on the company's progress and future outlook in the digital infrastructure sector.
AIB Data Centers' upcoming virtual investor roadshow is noted alongside a Technology-sector market where only 24 of 150 US stocks rose on October 14, 2026. For readers following Technology stocks on Pluang as of Oct 14, 2026 20:02 WIB: AXTI traded at USD 62.10 with 12% Sell / 88% Buy order activity and a typical hold time of 17 days; QBTS was USD 12.86 with 36% Sell / 64% Buy and 33 days hold; PANW stood at USD 382.20 with 53% Sell / 47% Buy and 82 days hold.
Transmission System Operators (TSOs) are increasingly investing in software like Energy Management Systems and grid planning tools to modernize aging infrastructure, enhance cybersecurity, and expand grid capacity. Cybersecurity remains their top con...
Air Canada will begin a new seasonal nonstop flight service between Montreal and Seville, Spain, starting September 8, 2027. This route is the only nonstop connection between North America and Seville, enhancing travel options for leisure and busines...
Air Canada announced it will start non-stop seasonal flights between Montréal and Seville, Spain, beginning September 8, 2027. This new route is the only direct connection between North America and Seville, enhancing travel options for Canadians and ...
CodeWall Ltd. has emerged from stealth with $4 million in pre-seed funding to develop AI-powered autonomous attack agents that simulate real-world cyberattacks on enterprises. These agents start from outside the network with no insider access, contin...
Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...
